Cargando…

Holding CoVID in check through JAK? The MPN-approved compound ruxolitinib as a potential strategy to treat SARS-CoV-2 induced systemic hyperinflammation

Detalles Bibliográficos
Autores principales:	Heidel, F., Hochhaus, A.
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Nature Publishing Group UK 2020
Materias:	Editorial
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7288260/ https://www.ncbi.nlm.nih.gov/pubmed/32528040 http://dx.doi.org/10.1038/s41375-020-0898-6

Ejemplares similares

The JAK1/2 inhibitor ruxolitinib in patients with COVID-19 triggered hyperinflammation: the RuxCoFlam trial
por: Hammersen, J., et al.
Publicado: (2023)

Ruxolitinib, a JAK1/2 Inhibitor, Ameliorates Cytokine Storm in Experimental Models of Hyperinflammation Syndrome
por: Huarte, Eduardo, et al.
Publicado: (2021)

P1542: RUXOLITINIB IN COVID-19 PATIENTS WITH DEFINED HYPERINFLAMMATION: THE RUXCOFLAM TRIAL
por: Birndt, Sebastian, et al.
Publicado: (2023)

Determinants of Covid19 disease and of survival after Covid19 in MPN patients treated with ruxolitinib
por: Palandri, Francesca, et al.
Publicado: (2023)

The Janus kinase 1/2 inhibitor ruxolitinib in COVID-19 with severe systemic hyperinflammation
por: La Rosée, F., et al.
Publicado: (2020)

P1011: PREDICTORS OF COVID-19 DISEASE AND SURVIVAL TO COVID-19 IN MPN PATIENTS TREATED WITH RUXOLITINIB
por: Palandri, F., et al.
Publicado: (2022)

Longer-term response to SARS-CoV-2 vaccine in MPN patients: Role of ruxolitinib and disease severity
por: Auteri, Giuseppe, et al.
Publicado: (2022)

Immune Dysregulation and Infectious Complications in MPN Patients Treated With JAK Inhibitors
por: Cattaneo, Daniele, et al.
Publicado: (2021)

Efficacy and safety of ruxolitinib in patients with newly-diagnosed polycythemia vera: futility analysis of the RuxoBEAT clinical trial of the GSG-MPN study group
por: Koschmieder, Steffen, et al.
Publicado: (2022)

The PIM inhibitor AZD1208 synergizes with ruxolitinib to induce apoptosis of ruxolitinib sensitive and resistant JAK2-V617F-driven cells and inhibit colony formation of primary MPN cells
por: Mazzacurati, Lucia, et al.
Publicado: (2015)

CoVid-19 related dactyitis
por: Salvatierra, Juan, et al.
Publicado: (2020)

Nanobiotechnology in combating CoVid-19
por: Ganapathy, Dhanraj, et al.
Publicado: (2020)

P1029: JAK2-CHIP IS ASSOCIATED WITH SIMILAR RISK OF CARDIOVASCULAR DISEASE AS JAK2-MPN
por: Grevet, Jeremy, et al.
Publicado: (2023)

Telemedicine against CoVID-19 crisis
por: Ajami, Sima, et al.
Publicado: (2020)

Nutritional recommendations for CoVID-19 quarantine
por: Muscogiuri, Giovanna, et al.
Publicado: (2020)

Éthique, déontologie et CoVid-19
por: Julien, Henri
Publicado: (2022)

Atomic Simulation of the Binding of JAK1 and JAK2 with the Selective Inhibitor Ruxolitinib
por: Kondratyev, Maxim, et al.
Publicado: (2022)

Hyperinflammation bei SARS-CoV-2-Infektion
Publicado: (2020)

Dead in the air- The need to adapt to CoVID adaptations
por: Kuehnel, Nicholas A., et al.
Publicado: (2021)

Comments on nutritional recommendations for CoVID-19 quarantine
por: Herrera-Peco, Iván, et al.
Publicado: (2021)

The CO-VID D-Lemma: A Call for Action
por: Holick, Michael F.
Publicado: (2022)

Data on steam inhalation in combating CoVid-19
por: Kumar, Barun Dev, et al.
Publicado: (2022)

JAK2 inhibitor persistence in MPN: uncovering a central role of ERK activation
por: Pandey, Garima, et al.
Publicado: (2022)

Use of the JAK Inhibitor Ruxolitinib in the Treatment of Hemophagocytic Lymphohistiocytosis
por: Keenan, Camille, et al.
Publicado: (2021)

From the Ketogenic Diet to the Mediterranean Diet: The Potential Dietary Therapy in Patients with Obesity after CoVID-19 Infection (Post CoVID Syndrome)
por: Barrea, Luigi, et al.
Publicado: (2022)

Diagnosis and treatment of MPN in real life: exploratory and retrospective chart review including 960 MPN patients diagnosed with ET or MF in Germany
por: Schmidt, Andreas, et al.
Publicado: (2023)

Changes in burn referrals and injuries during CoVid-19
por: Chu, H., et al.
Publicado: (2020)

Data on known anti-virals in combating CoVid-19
por: Akshayaa, L, et al.
Publicado: (2020)

The impact of JAK/STAT inhibitor ruxolitinib on the genesis of lymphoproliferative diseases
por: TÜRK, Can, et al.
Publicado: (2019)

Holding the Inflammatory System in Check: TLRs and NLRs
por: Holl, Eda K., et al.
Publicado: (2016)

Frequency of infections in 948 MPN patients: a prospective multicenter patient-reported pilot study
por: Crodel, Carl C., et al.
Publicado: (2020)

PB2176: MRNA OF MPL AND JAK2 GENES IN PLATELETS IS ASSOCIATED WITH THEIR ASPIRIN RESISTANCE IN MPN PATIENTS
por: Stolyar, Marina, et al.
Publicado: (2023)

Proliferative activity is disturbed in myeloproliferative neoplasms (MPN), myelodysplastic syndrome (MDS), and MDS/MPN diseases. Differences between MDS and MDS/MPN
por: Mestrum, Stefan G. C., et al.
Publicado: (2020)

Learning From Disasters: The CoVID-19 Fallout on Spine Care
por: Chapman, Jens R., et al.
Publicado: (2020)

Brain Awareness Week, CoVID-19 infection and Neurological Sciences
por: Federico, Antonio
Publicado: (2020)

Recommendations for school-going students post CoVid-19 in Bangladesh
por: Kabir, Humayun, et al.
Publicado: (2021)

Effect of environmental, economic and health factors on CoVid-19 transmission
por: Anam, Sobia, et al.
Publicado: (2021)

Is butyrate a natural alternative to dexamethasone in the management of CoVID-19?
por: K, Nithin K., et al.
Publicado: (2021)

Molecular docking analysis of quercetin with known CoVid-19 targets
por: Chandran, Sridevi Chandra Subash, et al.
Publicado: (2023)

Biology and Clinical Management of Myeloproliferative Neoplasms and Development of the JAK Inhibitor Ruxolitinib
por: Mascarenhas, J, et al.
Publicado: (2012)

Cannot write session to /tmp/vufind_sessions/sess_s2l1tlan0dnjs0nfij9aqvgnn6